KGMC will secure publications of this 'breakthrough technology' in respected medical and scientific journals and identify ideal partners to commercialise the technology
Acrongenomics has retained KGMC to introduce its Nano-Jeta technology platform to the world market.
KGMC introduces and markets advanced medical technologies.
With a diverse team of talented and respected professionals in medicine, science, business, finance, marketing and law from four continents, KGMC provides services and solutions essential to converting emerging technologies into viable business ventures.
KGMC will work with Acrongenomics to complete formal validations of the advanced Nano-Jeta platform, secure publications of this breakthrough technology in respected medical and scientific journals and identify ideal partners to commercialise the technology.
"Following a year of thorough study, our scientists and board of directors have confirmed that Acrongenomics' know-how in nanotechnology has resulted in compelling breakthroughs, significantly impacting our battle with various diseases such as cancer.
"We are convinced that Nano-Jeta technology platform can accelerate and enhance the commonly used real time PCR amplification process, so that it is rendered 100% accurate in detecting genetic diseases such as cancer.
"Neo-EpCam cancer detection assay is the first application utilising the Nano-Jeta technology.
"More so exciting is that the process takes less than two minutes.
"Because it is fast, inexpensive, easy to administer, non-invasive, accurate, specific and uses existing equipment, we are convinced that the technology will assist physicians in detecting genetic diseases quickly, accurately and early enough to potentially save lives and avoid much cost and anguish.
"Now confident in the technology, we will assist Acrongenomics in securing a partner to further develop and market such technology", says KGMC group president Bill Kanatas.
Acrongenomics is a publicly traded research and development nanobiotechnology company pioneering the development of uniquely advanced nano-molecular diagnostics for the life sciences industry.
The company is seeking to establish its proprietary nanotechnology platform as a global standard in molecular in vitro diagnostics.
Acrongenomics says it has successfully conducted laboratory tests and clinical trials for the cancer detection and quantification process.
The technology has been applied to major molecular diagnostics techniques such as polymerase chain reaction (PCR) and real-time PCR producing outstanding results in terms of sensitivity, reproducibility, specificity and speed with the use of conventional equipment, it says.
Since the completion of the Human Genome Project in 2000, the growing number of sequencing and functional genomic initiatives has resulted in the rapid growth of the molecular diagnostics field.
In 2005, the global market for molecular diagnostics is estimated to reach US$6.5 billion.
By 2010 the market is forecasted to expand to $12 billion and to $35 billion by 2015 (Research and Markets Report 2004).
There is considerable demand for new molecular diagnostic technologies.
So profitable is the molecular diagnostics market that pharmaceutical and biotechnology companies are highly focused in developing molecular diagnostics tests that can be used to individualise patient treatments.
With the validation and introduction of the Nano-Jeta technology platform, along with the support of KGMC, Acrongenomics says it is positioned to emerge as a leader in this rapidly expanding market segment.
KGMC consists of a diverse team of professionals focused on commercialising emerging medical technologies.
President and CEO Bill Kanatas is described as a distinguished Chicago business leader and entrepreneur specialising in growth-venture management and acquisitions.
Chief financial officer Thomas Matthews has illustrated expert financial guidance through the initiation, management, financing and completion of over $250 million in development projects and assets.
Scientific advisor Carlos Cordon-Cardo is one of the leading pathologists in the USA with over 25 years at the forefront of cancer research.
Cordon-Cardo serves as the director of the division of molecular pathology at New York City's Memorial-Sloan Kettering, said to be the USA'sforemost cancer treatment and research facility, and is associate professor of pathology at Cornell University Medical College.
Medical director Usama Hamden is an international lecturer with university appointments at Harvard Medical School, Boston University School of Medicine and Tufts University School of Medicine, as well as visiting professorships at numerous institutions internationally.
Clinical advisor Rafael Barrera is a physician, author and lecturer serving as attending physician at New York's Long Island Jewish Medical Center, North Shore University Hospital, and assistant professor at the Albert Einstein School of Medicine.
Corporate counsel Gary Green, principal of Sidkoff, Pincus and Green, specialises in securities, banking, and corporate law.
And finally, Senior vice president of marketing Chris Coyne brings 30 years of experience as an entrepreneur and executive, having co-founded two highly successful companies within the hospital services industry and now as president of both Coyne Group, an investment firm, and Coyne Foundation.
